Journal Scans
Trastuzumab for Treatment of Refractory/Relapsed HER2-Positive Adult B-ALL: Results of a Phase II GRAALL Study
Trastuzumab in Relapsed/Refractory HER2+ Adult ALL
P Chevallier, N Robillard, A Charbonnier, H Dombret, et al
20120020
2012 Jan 20
Blood
Trastuzumab for Treatment of Refractory/Relapsed HER2-Positive Adult B-ALL: Results of a Phase II GRAALL Study
Blood. 2012 Jan 20;[Epub Ahead of Print], P Chevallier, N Robillard, A Charbonnier, H Dombret, et al
TAKE-HOME MESSAGE
Abstract
Abstract
The aim of this Phase II study was to evaluate the efficacy and safety of trastuzumab, a humanized monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2), for adult patients with relapsed/refractory HER2-positive B-ALL. Fifteen patients, with a median age of 62 years, received trastuzumab according to the schedule approved for breast cancer patients i.e. 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly. The overall response rate was 13% with two patients...
